NCT00421889View on ClinicalTrials.gov

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Ovarian CancerEpithelial Ovarian CancerFallopian Tube CancerBladder Cancer
Interventions
DRUG

belinostat

DRUG

Paclitaxel

DRUG

Carboplatin

Trial Locations (11)

2100

The Finsen Center, Rigshospitalet, Copenhagen

2730

Research Facility, Herlev University Hospital, Herlev

21204

Greater Baltimore Medical Center, Baltimore

32804

Research Facility, Orlando

70006

Hematology & Oncology Specialists, LLC, Metairie

70433

Hematology and Oncology Specialists, LLC, Covington

92663

Gynecologic Oncology Associates, Newport Beach

02114

Massachusetts General Hospital Cancer Center, Boston

02905

Women & Infants Hospital of Rhode Island, Providence

G120YN

The Beatson West of Scotland Cancer Centre, Glasgow

SM2 5PT

The Royal Marsden NHS Trust, Surrey

Sponsors
All Listed Sponsors
lead

Valerio Therapeutics

INDUSTRY

NCT00421889 - A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | Biotech Hunter | Biotech Hunter